Trident Lifeline Ltd — Important, 09-06-2026: Company Update

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.

Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com

Factory Address: Plot No. 4240, Road No. 42, Sachin GIDC, Surat, Gujarat - 394230, India.

Date: 09.06.2026

BSE Limited

P. J. Towers,

Dalal Street, Fort,

Mumbai – 400001.

Stock ID: TLL

Scrip Code: 543616

Dear Sir/Ma’am,

Sub: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations

and Disclosure Requirements) Regulations, 2015

Dear Sir/Ma’am,

We wish to inform to the Exchange that TRIDENT MEDIQUIP LIMITED (TML) (CIN:

U33309GJ2019PLC110421), a subsidiary company has made Private Placement of equity

shares to other shareholders. Pursuant to the above allotment to other shareholders, the

shareholding of Trident Lifeline Limited in Trident Mediquip Limited stands at 58.84%.

We enclosed herewith the details required under Regulation 30 of SEBI (LODR) Regulations,

2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated

January 30, 2026 as Annexure – A.

Thanking You.

Yours faithfully,

FOR TRIDENT LIFELINE LIMITED

NIKITA SHARMA

COMPANY SECRETARY AND COMPLIANCE OFFICER

M. NO.: A60595

----------------Page (0) Break----------------

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.

Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com

Factory Address: Plot No. 4240, Road No. 42, Sachin GIDC, Surat, Gujarat - 394230, India.

Annexure-A

Information under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular No.

HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Sr.

No.

Particulars Details

1 Name of the target entity,

details in brief such as size,

turnover etc.

TRIDENT MEDIQUIP LIMITED (CIN:

U33309GJ2019PLC110421) Company incorporated

under the provisions of the Companies Act, 2013,

having its Registered Office in Surat, Gujarat

Capital Details:

Authorized Share Capital: Rs. 10,00,00,000/-

divided into 1,00,00,000 Equity Shares of Rs.10/-

each

Paid-up Share Capital: Rs. 9,97,00,000/- divided

into 99,70,000 Equity Shares of Rs.10/- each

Turnover: 27.31 Cr

2 Whether the acquisition would

fall within related party

transaction(s) and whether the

promoter/ promoter group/

group companies have any

interest in the entity being

acquired? If yes, nature of

interest and details thereof and

whether the same is done at

“arm’s length”

Yes, TRIDENT MEDIQUIP LIMITED, Subsidiary of

Trident Lifeline Limited, therefore is a related

party. Also Mr. Amit Bhupendra Halvawala and Mr.

Chetan Chandrakant Jariwala (director’s Relative of

Rupaben Jariwala) are member cum Director, Mr.

Hardik Jigishkumar Desai members and all of above

are part of promoters/promoter group/board of

acquiring Company i.e being Trident Lifeline

Limited (The Company), have an interest in the

entity being acquired (TML).

The transaction is being undertaken on an arm's

length basis.

3 Industry to which the entity

being acquired belongs

Medical Device Industry

4 Objects and impact of

acquisition (including but not

limited to, disclosure of reasons

for acquisition of target entity, if

its business is outside the main

line of business of the listed

entity)

TRIDENT MEDIQUIP LIMITED is a subsidiary of the

company. In order to further allotment of shares to

other shareholders, percentage of holding its stake

in TML stands at 58.84%.

----------------Page (1) Break----------------

Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA.

Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com

Factory Address: Plot No. 4240, Road No. 42, Sachin GIDC, Surat, Gujarat - 394230, India.

5 Brief details of any

governmental or regulatory

approvals required for the

acquisition.

NA

6 Indicative time period for

completion of the acquisition

NA

7 Consideration - whether cash

consideration or share swap

and details of the same;

NA

8 Cost of acquisition or the price

at which the shares are

acquired;

NA

9 Percentage of shareholding /

control acquired and / or

number of shares acquired;

Pre holding: 59.17%

Post holding: 58.84%

10 Brief background about the

entity acquired in terms of

products/line of business

acquired, date of incorporation,

history of last 3 years turnover,

country in which the acquired

entity has presence and any

other significant information (in

brief);

Date of incorporation: October 19, 2019

Product/line of business: Medical Device Industry

Last 3 years' turnover:

Financial year 2023-24- 20.58 Cr.

Financial Year 2024-25- 21.29 Cr.

Financial Yeat 2025-26- 27.31 Cr.

Presence of entity: India

----------------Page (2) Break----------------